New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics


December 2017

Welcome to the December 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the December issue!

The PharmSource Team

CDMO Acquisitions Build Strategic Supplier Base

by Jim Miller, Founder and President

This has been another big year for acquisitions in the contract development and manufacturing organization (CDMO) industry. In the first three quarters of 2017, there have been 25 deals in which a CDMO was the acquisition target.

With just three months left in 2017, the final number of deals is likely to trail 2016 (34 CDMO acquisitions), but the total value of the transactions is likely to exceed $20 billion, which will far exceed 2016’s total…read on

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity


Lead Type December 2017 YTD 2017
Early Development 97 1245
Late Development 94 1145
Biologic 98 1133
Small Molecule 138 2406
Parenteral 124 1244
Oral 93 1079
New Financings 35 1058
Total Drug Leads 408 4163
Total Device &
Diagnostic Leads
117 1471

*Total leads include acquisitions/alliances, company acquisition/alliances and events.

Pipeline Tip

ACADIA initiates the Phase III HARMONY study with NUPLAZID for the treatment of hallucinations and delusions associated with dementia-related psychosis:

  • Therapeutic Area: Antipsychotic & Alzheimer’s disease/Dementia
  • Dosage Form: Tablet
  • API: Chemical – Normal potency

Get deeper information about the likely upcoming needs of Rebiotix, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a US public company that discovers and develops disulfide-rich peptides, alternatives to antibodies and new chemical entities to treat life-threatening diseases. It plans to raise $60 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund the clinical development of PTG-100, PTG-200 and PTG-300…read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on AxioMed LLC, Inc.

AxioMed is a US private company that focuses on products to address spinal function in patients with degenerative spine disease. It raised $10 million in the completion of a venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support IDE clinical trials and commercialization efforts for thier Freedom cervical disc…read on

Dose CMOs Stuck in Idle

PharmSource’s just-released trend report, Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition, reveals several factors for the dose CMO industry’s relatively poor performance in 2016:

1. Rebound in drug development since 2013 is too recent to benefit dose CMOs

2. Heavy investment in captive capacity by global bio/pharma companies

3. Declining significance of dose manufacturing in drug cost of goods as new drugs with high value APIs dominate the pipeline


Jim Miller is speaking

Jim Miller will be speaking in Frankfurt, Germany on the 23rd of October at the CPhI Pre-Connect Conference on trends in the contract manufacturing industry.

He will also be speaking in San Diego, CA on the 13th of November at the AAPS Annual Meeting on trends in the contract manufacturing industry.

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).